166 results about "Memory Losses" patented technology

The invention provides compositions comprising one or more long chain polyunsaturated fatty acids, nitric oxide releasing compounds, and medium chain triglycerides and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.

Compositions comprising one or more unsaturated fatty acids and one or more nitric oxide releasing compounds, and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.

The invention discloses a new traditional Chinese medicine composition for treating memory loss and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicinal herbs: fructus alpiniae oxyphyllae, rhizoma acori graminei, dangshen, angelica sinensis, raw astragalus mongholicus, ginseng, radix paeoniae alba, root of common peony, ligusticum wallichii, radix salviae miltiorrhizae, chrysanthemum, root of kudzu vine, radix angelicae, prepared rehmannia root, motherwort, rhizoma sparganii, curcuma zedoary, cortex albiziae, polygala tenuifolia, styrax Asiatic styrax, white atractylodes rhizome, aweto, scutellaria baicalensis, polygonum multiflorum, red flower, radix curcumae and fruit of Chinese wolfberry. The traditional Chinese medicine composition can be prepared into any one oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of hypomnesis, thinking logic disorder and incomplete language expression as well as memory loss, no recognition of family and relatives and friends, no capability of self-care life, changeable and violent characters in serious conditions, or dull spirit and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking.

The invention relates to a stable preparation of phosphatidylserine and a preparation method, application as well as an application product of the stable preparation. The preparation method comprises the following step of processing the phosphatidylserine through microencapsulation, micro-pelletization or liposome encapsulation. The stable preparation of the phosphatidylserine can be independently applied as a medicine or can be added into daily foods, drinks and health-care products, also has an important effect on health care of brains while guaranteeing the color and the taste of the daily foods and the drinks of people and is of great benefit to brain disorder such as nutritional supplement of brain development of students, overstrain of nerves of the adults, and memory loss, brain atrophy and senile dementia of the middle aged and elderly people.

This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and / or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.

The invention discloses a batch A3C reinforcement learning method for an agent to explore a 3D maze. In order to achieve the goal of relatively short training time and small memory loss, the inventionuses a batch-based reinforcement learning method to train a neural network. The neural network is divided into two parts. The first part mainly consists of several convolution layers and MLP, and thelow-dimensional representation of the original screen pixels is obtained. The second part is an LSTM (Long-Short-Term Memory) model. The input of the LSTM is the output of the MLP of the first part,and the cell output of the last time step of the LSTM is circumscribed with two MLPs, which are respectively used to predict the probability distribution of the action a in the current state and the prediction of the state value v in the current state. Combining the efficient reinforcement learning algorithm and depth learning method, the agent can explore 3D maze independently, and the agent cansuccessfully explore 3D maze environment with relatively short training time and small memory consumption.

The invention provides a method for preparing a 5,6,7,4'-tetrahydroxyflavone compound, which is characterized by comprising the following steps: taking breviscapinun as a raw material, and performing heating reflux reaction between the breviscapinun and alcohol under the catalysis of acid, namely adding 200 to 500 ml of alcohol substance and 1 to 3 ml of 4 to 5 percent acid into 12 to 20 g of the breviscapinun for the heating reflux reaction; and filtering a product, and drying to a constant weight to obtain 5,6,7,4'-tetrahydroxyflavone shown in a formula I. Experiments prove that the 5,6,7,4'-tetrahydroxyflavone shows obvious strengthening effect on acquisition, consolidation and representation of brain memory of a mice model of alzheimer disease, has obvious improving effect on learning memory of the mice model with memory loss caused by anisodine of an M-cholinergic inhibitor, and can obviously improve the recent memory and long-term memory capacities of mice. The experiments also prove that the 5,6,7,4'-tetrahydroxyflavone has the effect of treating arthritis, and also has good treating effects on diabetes mellitus and osteoporosis.

The present invention concerns the methods and compositions for treating depression and other behavioral and / or emotional disorders of the central nervous system by administering an agonist of hedgehog signaling. Other disorders amenable to treatment by the subject method include attention deficit hyperactive disorders, non-Alzheimer dementia, and various symptoms of memory loss. The present invention also concerns the methods and compositions for enhancing memory and / or cognitive functions, both in a patient suffering from ailment affecting these functions, and in a subject with no diagnosed deficit in memory or cognitive function. The methods and compositions of the present invention stimulate neurogenesis and differentiation, and enhance synaptic transmission of neurons.

This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.

The invention discloses a system and method for assisting an Alzheimer's disease patient in searching object based on virtual reality. The system and the method can be applied to a wearable device. The method comprises the steps of monitoring an electroencephalogram signal of the Alzheimer's disease patient through an electroencephalogram sensor; judging whether the patient is in a brain memory loss state or not according to the electroencephalogram signal; collecting reality scene images around the patient through a video recorder when the patient is in the brain memory loss state; identifying behavior action information of the patient from the collected reality scene images; matching virtual scene images related to object storage experiences of the patient from a memory according to the behavior action information; identifying the object storage location information of the patient from the virtual scene images; and controlling a loudspeaker to play the object storage location information, thereby guiding the patient to search stored objects. Through application of the method and the system, the patient is assisted in searching required objects rapidly through virtualizing the virtual scene images related to object storage experiences of the patient.

The present invention provides a cloud editing live editing method and a corresponding system which can perform edition of a local video and a webpage video and event a webpage record screen, and canadd marking information such as characters, images or watermarks for the editing video as required to allow the video information to be much richer and more detailed so as to allow watchers to rapidlyobtain and accurately understand the information provided by the edition video and combine the multiple sections of mutually associated videos to allow the information published each time to be morecomprehensive and much wider. The operation mentioned above is performed at the cloud with no need for transition of the local operation so as to greatly shorten the operation time and effectively reduce the memory loss caused by the local operation. Through the mode mentioned above, the various videos are rapidly and conveniently edited and published, and the cloud editing live editing method andthe corresponding system can be especially suitable for webpage operation, software demonstration courses and making of video information such as game demonstration videos so as to obviously improvethe physical experience of the video information on the premise of ensuring the whole recording of the video information.

Compositions, kits and methods are provided for promoting brain and cardiovascular health, preventing or treating neurological and vascular disorders. In one embodiment, the composition comprises Rhodiola rosea (root), Ginkgo biloba (leaf), Panax notoginseng (root), and Ligusticum chuanxiong (rhizome). The composition can be used as pharmaceuticals or nutraceuticals for promoting general brain health, maintaining a healthy brain, and all neurological disorders such as memory loss, ischemic stroke, neurodegenerative diseases (e.g., Huntington's disease, Alzheimers's disease, and amyotrophic lateral sclerosis) and vascular diseases such as arteriosclerosis, congestive heart failure, hypertension, cardiovascular diseases, cerebrovascular diseases, renovascular diseases, mesenteric vascular diseases, pulmonary vascular diseases, ocular vascular diseases, peripheral vascular diseases, peripheral ischemic diseases, and the like.

The present disclosure relates to a composition of an extract of fruits of Emblica officinalis selected from the group consisting of liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydro alcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, a powder of a pectinase treated water extract of fruits of Emblica officinalis, and combinations thereof; a method of preparing such compositions of extract of fruits of Emblica officinalis, more particularly which has application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss especially in Alzheimer's disease.

The invention relates to novel polymorph crystal forms A and B of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide: The compounds and pharmaceutical compositions thereof are useful for activating a malfunctioned cholinergic neuron that is associated with memory loss disturbances.

The present invention provides novel uses of tanshinone derivatives as acetylcholinesterase inhibitors, and in diseases associated with depletion of acetylcholine, such as Alzheimer's disease, insomnia, vascular dementia, memory loss, attention disorders, and other sleep disorders. New uses in the treatment of cognitive impairment diseases. The active compound is generally found in the roots of Salvia genus, especially Salvia miltiorrhiza.

The invention provides a game interactive interface display method and apparatus, an electronic device and a storage medium. The method comprises the steps of performing static frame screen capture on a current main interface of a virtual scene to obtain a static frame screen capture image when a preset operation on a graphic user interface is monitored, and disabling the rendering of the virtual scene; generating a first user interface according to the static frame screen capture image and popping up and displaying the first user interface; and when a closing operation on the first user interface is received, closing the first user interface to release the static frame screen capture image, and enabling the rendering of the virtual scene to return to the current main interface of the virtual scene. According to the display method and apparatus, the electronic device and the storage medium, the package resource size can be reduced, the memory loss caused by real-time rendering of game scenes is reduced, the frame jamming and dropping situations of games are reduced, the immersive sense of the game scenes is improved, and better experience is brought for users.

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.

The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or COX-2 at therapeutically relevant doses, these compounds are far less likely to cause gastrointestinal ulceration than is indomethacin, which is known to inhibit both COX-1 and COX-2. Certain of the compounds inhibit the activity of DAO at therapeutically relevant doses. Among the memory disorders that can be treated are AD, mild cognitive impairment (MCI; a common precursor to AD), and memory loss or cognitive impairment associated with vascular dementias, amnesia, dementia, AIDS dementia, Huntington's Disease, hydrocephalus, depression, Pick's Disease, Creutzfeldt-Jakob Syndrome, electroconvulsive therapy, or Parkinson's Disease.

The invention discloses a subhealth regulating traditional Chinese medicine composition and the preparation method thereof. The subhealth regulating traditional Chinese medicine composition is made of medical raw materials with the following proportioning by weight: 25 g to 275 g of raw milkvetch root , 5 g to 25 g of american ginseng or 25 g to 175g of beach silvertop root or 25 g to 175 g of pilose asiabell root, 25 g to 175 g of raw Chinese yam or atractylodes macrocephala, 0 to 100 g of epimeddium or Indianmulberry, 25 g to 175 g of hyacinth bean, 5 g to 25 g of notoginseng or red sage root , and 5 g to 45 g of fruit orange magnoliavine. The invention also comprises the preparation method of the subhealth regulating traditional Chinese medicine composition. The product of the invention can improve the subhealth symptoms of tiredness and fatigue, wheezy phlegm in the throat, much thick sputum, prickle in both rib-sides, hiccup and belching, abdominal distension and sugar excrement, short breath and distinclination to talk, shoulder and neck rigidity, insomnia and anxiety, asthenia heat and apontaneous perspiration, darkish or dimmish and yellowish complexion, obesity (at the initial stage), headache, astriction, sexual function decline, attention deficit, memory loss, poor appetite, dryness of the skin, flaccidness and wrinkle, acne, chloasma, leukorrh, abnormal menstrual period, grey beard and hair, show temper and irascibility, hunger of stomach, stomach yin, mental confusion, and chest distress which are caused by blood stasis and vital energy retardation, slight deficiency of spleen and stomach, stagnation of qi and blood stasis, dysfunctional state of the viscera, organism imbalance of yin and yang. The total effective rate of the invention reaches above 97 percent, and the taking is secure.

The invention relates to compounds of formulawherein variables are defined herein.It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.

Composition and methods of alleviating impaired mental function and memory loss in mammals and reducing the recovery time from anaesthesia in age mammals, comprising treating the mammal with a non-toxic, enhancing effective amount of a cell membrane permeant calcium buffer. The buffer is preferably a calcium ion chelating agent having a KD selected from the range 1x10-4 to 1x10-8 Molar and being essentially calcium ion-selective over other metal ions. A most preferred buffer is BAPTA-AM.

The invention discloses a method for preparing total flavonoids from traditional Chinese medicine psoralea corylifolia and a new application of the total flavonoids in psoralea corylifolia to preparation of drugs for preventing or treating the AD (alzheimer's disease). According to different polarities of main ingredients contained in the psoralea corylifolia, low-polarity monoterpene phenols with toxic and side effects are removed through petroleum ether degreasing, flavonoids are extracted with ethyl acetate, the total flavonoids in the psoralea corylifolia are obtained through impurity removal and refinement with activated carbon, and the purity can reach 50% or higher. The method is economical, efficient and suitable for industrial production. In-vitro activity research confirms that the main flavonoids contained in the psoralea corylifolia have different degrees of inhibition activity for multiple related targets of the AD; animal experiments prove that the total flavonoids in psoralea corylifolia can remarkably improve neurodegeneration memory loss symptoms of AD model mice through oral medication, have no toxic and side effects after long-term medication and can be used for preparing drugs for preventing or treating the AD.

The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.

In a first aspect, the present invention relates to a method for prevention or treating memory impairment and / or a neurodegenerative condition, disorder or disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound targeting a miRNA or any precursor, or targeting the activity of said miRNA or any precursor thereof. In particular, the present invention relates to a method wherein the targeted miRNA is miR-34. Moreover, the present invention relates to a method for improving memory functionality in a subject suffering from memory loss, said method comprises the reduction or reducing the level of miR-34 levels or precursor molecule levels in brain tissue of said subject administering to the subject a therapeutically effective amount of a compound targeting miR-34 or any precursor thereof.Moreover, the present invention relates to a method of inducing memory loss in an individual comprising administering to said individual an effective amount of one or more compounds having the functionality of miR-34, in particular of miR-34c or any precursor thereof. In addition, a method for diagnosing or predicting memory impairment and / or neurodegenerative condition, disorder or disease is provided. Finally, the present invention relates to a pharmaceutical composition containing a compound targeting miR-34 or precursor molecules thereof.

Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.

The invention relates to a log synchronization method and device, and belongs to the technical field of data processing. The method comprises the following steps: reading a transaction log from a source database and storing the transaction log into a plurality of read annular queues; storing the transaction logs in the read annular queues into a consumption annular queue, and sending the transaction logs in the consumption annular queue to a thread connected with a target database; and writing the transaction log into the target database by the thread and recording a log code corresponding tothe successfully written transaction log. According to the method, the annular queue is adopted to store the transaction logs, so that the transaction log storage speed is increased, and the memory loss is greatly reduced.

There is a need for solutions that monitor memory loss with reduced caretaker involvement. This need can be addressed by, for example, selecting a first question from a group of multiple questions to ask a user of a computing device based one or more attributes associated with each question in the group of multiple questions; receiving a first answer by the user of the computing device to the first question; determining, from the first answer, one or more behavioral attributes associated with user response to the first question; and determining, based on the one or more behavioral attributes, a cognitive capability of the user of the computing device.